FDA Agrees on Phase 3 Design & Primary Endpoint for Belapectin in MASH Cirrhosis
GALT sits 50% above its 52-week low of $1.85.
Summary
Galectin Therapeutics announced positive FDA feedback, securing agreement on the Phase 3 trial design and regulatory path for its lead drug, belapectin, in MASH cirrhosis.
Key Events · Product Development and Regulatory · GALT
-
FDA Agreement on Phase 3 Design
The company reached agreement with the FDA on the primary endpoint (composite liver outcome including prevention of large esophageal varices) and overall study design for the Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension.
-
Clear Regulatory Pathway
The FDA confirmed that the proposed composite outcome endpoints and study framework are appropriate for a traditional full approval pathway, providing a clear path towards a broad indication.
-
Partnership Exploration
Galectin Therapeutics is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin, with Phase 3 protocol submission anticipated in Q3 2026.
Analysis · GALT · Life Sciences
Galectin Therapeutics received positive feedback from the FDA on its lead drug, belapectin, for MASH cirrhosis and portal hypertension. The FDA agreed on the Phase 3 study design, primary endpoint, and regulatory pathway for potential full approval. This clarity significantly de-risks the development program and strengthens the company's position as it seeks strategic and financial partners to fund the pivotal trial, which is crucial given its previously reported liquidity challenges and cash runway to May 2027.
At the time of this filing, GALT was trading at $2.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.4M. The 52-week trading range was $1.85 to $7.13. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.